Genome-wide CRISPR-Cas9 knockout screens have shown that, when KRAS is activated, specific gene deletions can either accelerate or suppress tumor growth, revealing key metabolic weaknesses that could be targeted therapeutically. The gene discussed is KRAS; the disease is neoplasm.